Skip to content

Multicenter double-blind double-simulated randomized controlled trial of activating renal blood circulation and ovarian stimulation infusion in treating ovarian dysfunction (ovulation failure infertility)

the reactive mechanism study of improving ovarian of gonadotropins in activating renal blood circulation and ovarian stimulation scheme in treating ovarian dysfunction (ovulation failure infertility)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-ICR-15006657
Enrollment
Unknown
Registered
2015-06-21
Start date
2012-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian dysfunction (ovulation failure infertility)

Interventions

the treating group:activating renal blood circulation and ovarian stimulation infusion
the control group:clomiphene

Sponsors

China Academy of Traditional Chinese Medicine Xiyuan Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. primary and secondary infertility participants who were under 35 years old not contraceptive 1 year or over 35 years old not contraceptive 6 month; 2. Conform to the diagnostic criterias of dysfunctional uterine bleeding, polycystic ovary syndrom, hyperprolactinemia, Luf follicle unruptured syndrome, luteal phase deficiency and diminished ovarian reserve; 3. Syndrome differentiation of traditional Chinese medicine is kidney deficiency and blood stasis; 4. During the treatment, couples live together and have normal sex life; 5. Each participant freely signs the informed consent.

Exclusion criteria

Exclusion criteria: 1. Infertility caused by congenital brith defect or deformity; 2. Infertility caused by genetic factors; 3. Infertility caused by oviduct, immune factors, endometriosis, uterine muscle adenopathy, uterine fibroids, uterine dysplasia; 4. male reproductive dysfunction; 5. with cardiovascular, liver, kidney and hematopoietic system illness or psychiatric patients; 6. Drug allergy to investigational drugs.

Design outcomes

Primary

MeasureTime frame
Ovulation rate;pregnancy rate;TCM symptom score;endometrium;diameter of dominant follicle;Sex hormones;

Secondary

MeasureTime frame
blood routine examination;urinary routine examination;stool routine test;blood coagulation test;electrocardiography;hepatic and renal function test;

Countries

China

Contacts

Public ContactMa Kun
makun12348@sina.com+86 13910218105

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026